Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Reblozyl (luspatercept by Year
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. reported growth YoY (%) (%)
Merck Reblozyl (luspatercept: 42.0% in FY2025, down 38.0 pts from a year earlier.
Latest, FY2025
42.0%
Period ended Dec 31, 2025
Change on a year earlier
-38.0 pts
80.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Alliance Revenue – Reblozyl (3) | 525 | 371 | 41 | 432 | 303 | 42 | 93 | 68 | 37”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 42.0% | -38.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 80.0% | +43.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 37.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
Cite this data
StockData. (2026). Merck Reblozyl (luspatercept (%), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-reblozyl-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.